Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1982 Apr;21(4):685–687. doi: 10.1128/aac.21.4.685

In vitro comparison of N-formimidoyl thienamycin (MK0787) and Azlocillin with three aminoglycosides and ticarcillin against Pseudomonas aeruginosa.

A J Matzkowitz, A L Baltch, R P Smith, N T Sutphen, M C Hammer, J V Conroy
PMCID: PMC181971  PMID: 6805426

Abstract

The activities of N-formimidoyl thienamycin and azlocillin were compared with those of tobramycin, gentamicin, amikacin, and ticarcillin against 175 Pseudomonas aeruginosa isolates, including 24 strains with known mechanisms of resistance to aminoglycosides. The 50% mean inhibitory concentration for azlocillin was lower than for ticarcillin, but the 90% mean inhibitory concentration was similar for both drugs. All susceptible and multidrug-resistant strains were susceptible to N-formimidoyl thienamycin.

Full text

PDF
685

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baltch A. L., Griffin P. E. Pseudomonas aeruginosa bacteremia: a clinical study of 75 patients. Am J Med Sci. 1977 Sep-Oct;274(2):119–129. [PubMed] [Google Scholar]
  2. Baltch A. L., Hammer M., Smith R. P., Sutphen N. Pseudomonas aeruginosa bacteremia: susceptibility of 100 blood culture isolates to seven antimicrobial agents and its clinical significance. J Lab Clin Med. 1979 Aug;94(2):201–214. [PubMed] [Google Scholar]
  3. Barry A. L., Thornsberry C., Jones R. N., Gavan T. L. In vitro activity of mezlocillin and azlocillin compared with that of four other penicillins and two aminoglycosides. Cleve Clin Q. 1980 Winter;47(4):311–319. doi: 10.3949/ccjm.47.4.311. [DOI] [PubMed] [Google Scholar]
  4. Brown J. E., Del Bene V. E., Collins C. D. In vitro activity of N-formimidoyl thienamycin, moxalactam, and other new beta-lactam agents against Bacteroides fragilis: contribution of beta-lactamase to resistance. Antimicrob Agents Chemother. 1981 Feb;19(2):248–252. doi: 10.1128/aac.19.2.248. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Coppens L., Klastersky J. Comparative study of anti-pseudomonas activity of azlocillin, mezlocillin, and ticarcillin. Antimicrob Agents Chemother. 1979 Mar;15(3):396–399. doi: 10.1128/aac.15.3.396. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Flick M. R., Cluff L. E. Pseudomonas bacteremia. Review of 108 cases. Am J Med. 1976 Apr;60(4):501–508. doi: 10.1016/0002-9343(76)90716-6. [DOI] [PubMed] [Google Scholar]
  7. Fu K. P., Neu H. C. Azlocillin and mezlocillin: new ureido penicillins. Antimicrob Agents Chemother. 1978 Jun;13(6):930–938. doi: 10.1128/aac.13.6.930. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Horadam V. W., Smilack J. D., Montgomery C. L., Werringloer J. In vitro activity of N-formimidoyl thienamycin (MK0787), a crystalline derivative of thienamycin. Antimicrob Agents Chemother. 1980 Oct;18(4):557–561. doi: 10.1128/aac.18.4.557. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Kropp H., Sundelof J. G., Kahan J. S., Kahan F. M., Birnbaum J. MK0787 (N-formimidoyl thienamycin): evaluation of in vitro and in vivo activities. Antimicrob Agents Chemother. 1980 Jun;17(6):993–1000. doi: 10.1128/aac.17.6.993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. König H. B., Metzger K. G., Mürmann R. P., Offe H. A., Schacht P., Schröck W. Azlocillin-ein neues Penicillin gegen Pseudomonas aeruginosa und andere gramnegative Bakterien. Infection. 1977;5(3):170–182. doi: 10.1007/BF01639754. [DOI] [PubMed] [Google Scholar]
  11. Livingston W. K., Elliott A. M., Cobbs C. G. In vitro activity of N-formimidoyl thienamycin (MK0787) against resistant strains of Pseudomonas aeruginosa, Staphylococcus epidermidis, Serratia marcescens, and Enterococcus spp. Antimicrob Agents Chemother. 1981 Jan;19(1):114–116. doi: 10.1128/aac.19.1.114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Phaneuf D., Neu H. C. Agar disk diffusion susceptibility characteristics of azlocillin, carbenicillin, mezlocillin, piperacillin, and ticarcillin. Antimicrob Agents Chemother. 1979 Nov;16(5):625–630. doi: 10.1128/aac.16.5.625. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Tutlane V. A., McCloskey R. V., Trent J. A. In vitro comparison of N-formimidoyl thienamycin, piperacillin, cefotaxime, and cefoperazone. Antimicrob Agents Chemother. 1981 Jul;20(1):140–143. doi: 10.1128/aac.20.1.140. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Wise R., Andrews J. M., Patel N. N-formimidoyl-thienamycin a novel beta-lactam: an in-vitro comparison with other beta-lactam antibiotics. J Antimicrob Chemother. 1981 May;7(5):521–529. doi: 10.1093/jac/7.5.521. [DOI] [PubMed] [Google Scholar]
  15. Wise R., Gillett A. P., Andrews J. M., Bedford K. A. Activity of azlocillin and mezlocillin against gram-negative organisms: comparison with other penicillins. Antimicrob Agents Chemother. 1978 Apr;13(4):559–565. doi: 10.1128/aac.13.4.559. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES